|Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir||Pres, CEO & Chairman||861.24k||N/A||1953|
|Mr. Jeffrey A. Rona||Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer||494.5k||N/A||1968|
|Mr. Thomas Michael Perone J.D., M.B.A.||Gen. Counsel, Chief Compliance Officer & Corp. Sec.||633.37k||N/A||1965|
|Dr. Matthew J. During Ph.D., M.D., DSc, FACP, FRACP||Founder & Member of Scientific Advisory Board||N/A||N/A||1957|
|Mr. Jason Tardio M.B.A.||Chief Commercial Officer & COO||N/A||N/A||1978|
|Ms. Lora Pike||Sr. Director of Investor Relations & PR||N/A||N/A||N/A|
|Ms. Suzanne K. Wakamoto SHRM-SCP, SPHR||Sr. VP of HR||N/A||N/A||N/A|
|Dr. Dirk Haasner||Sr. VP of Global Manufacturing & CMC QA||N/A||N/A||1965|
|Dr. Claude Nicaise M.D.||Head of R&D||N/A||N/A||1953|
|Mr. Luke Rosen||Sr. VP of Accelerated Devel. & Community Engagement||N/A||N/A||N/A|
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 9.